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*e purpose of this experimental clinical study was to assess the eﬀects of dark adaptation and acute changes in glycemia on retinal
vessel diameters in men. *e study included 14 patients (mean age 63 years, range 48–74 years) with type 2 diabetes mellitus and
minimal or no diabetic retinopathy. Retinal vessel diameters were assessed using infrared photography before and after dark
adaptation, ﬁrst while fasting and then at peak hyperglycemia during an oral glucose tolerance test (OGTT). Dark adaptation was
accompanied by retinal vasodilatation, both during fasting (mean glycemia 7.6± 1.7mM) and postprandial hyperglycemia (15.7±
4.2mM). When fasting, the increase in vein diameter during dark adaptation was 2.0% after 20min (P � 0.018) and 2.9% after
40min (P � 0.010). When subjects were hyperglycemic, the increase during dark adaptation was 2.8% for retinal vein diameters
(P � 0.027) and 2.0% for retinal artery diameters after 20min (P � 0.002) and 1.7% for retinal artery diameters after 40min
(P � 0.022). For identical conditions of light/dark adaptation, retinal vessels were dilated when subjects were fasting compared to
postprandial hyperglycemia. *us, darkness and fasting were both associated with retinal vasodilation in this short-term ex-
periment in patients with type 2 diabetes. Future studies should determine whether both the stimuli of vasodilation lead to retinal
hyperperfusion, which would support that they may be involved in the aggravation of diabetic retinopathy.
1. Introduction
Development of diabetic retinopathy and progression to
proliferative diabetic retinopathy are accompanied by di-
lation of the retinal veins [1–3]. It is of interest to identify
risk factors for retinal vasodilation, especially the ones that
aremodiﬁable, because the information thus obtained can be
used in the search of targets for intervention. Factors of
speciﬁc interest are the adaptation of the eye to changes in
ambient light and its adaptation and changes in glucose
levels, notably in diabetes.
Dark adaptation is accompanied by decreasing oxygen
tension and increasing lactate production in the retina [4–7]
and an increase in retinal blood ﬂow, part of which might be
mediated by blood vessel dilation [8–10].
Retinal vessel dilation occurs in response to experimental
hypoxia and ﬂicker stimulation [11–13], and lower glycemia
suppresses retinal electroretinographic signaling and dark
adaptation. Hence, there is a reason to suspect that hypogly-
cemia may dilate retinal vessels [14–17]. While some experi-
ments have found abnormal autoregulation of blood ﬂow in the
retina in diabetes, the relation between light exposure, glycemia,
and blood ﬂow outlined above may also exist in diabetes, and
there is a reason to suspect that it may contribute to the de-
velopment and progression of retinopathy in diabetes [18–21].
*e objective of the present study was to examine the
acute concomitant eﬀects of dark adaptation and changes in
glycemia levels on retinal vessel diameters in patients with
type 2 diabetes.
2. Materials and Methods
*is experimental clinical study included 14 patients with
type 2 diabetes mellitus, 9 men and 5 women, aged 48–74
years (mean± SD 62.6± 7.5 years; Table 1). Best-corrected
visual acuity (Snellen) was 0.9 or better in all eyes. *e
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patients had mild (ETDRS level< 35) or no diabetic reti-
nopathy and no study eye had macular edema. Exclusion
criteria were eye diseases other than diabetic retinopathy,
untreated arterial hypertension, and major systemic diseases
other than diabetes. All 14 patients were recruited from the
internal medicine outpatient clinic of Rigshospitalet; 13 were
treated with one or more oral antidiabetic agents, while one
was treated by diet alone. Four patients were treated by
insulin. *e study was approved by the Danish National
Committee on Biomedical Research Ethics and conducted
with the participants’ informed consent according to the
Helsinki Declaration II. *e study was registered at
Clinicaltrials.gov (NCT01136902).
Infrared scanning laser fundus photography (Spectralis
HRA+OCT, Heidelberg Engineering, Heidelberg, Germany)
was made over a 55-degree angle centered on the optic disc
with a nominal resolution of 768 × 768 pixels. A com-
puterized dark adaptometer (AdapDx, MacuLogix, Inc.,
Middletown, PA, USA) was used in three patients to verify
that full dark adaptation had been obtained at the end of the
examination [22].
Oral glucose tolerance testing (OGTT) was performed by
having the patients ingest 75 g of glucose dissolved in 250mL
of water. *e subsequent hyperglycemia was expected to
reach its peak after 1.5 hours. *e experiments were made
between 8 am to 12 pm after an overnight fast and the pa-
tients not having taken their antidiabetic agents since the
evening before.
Study procedures included determination of best-
corrected visual acuity (Snellen), transfoveal optical co-
herence tomography (Cirrus™ HD-OCT, Carl Zeiss Meditec
AG, Jena, Germany), infrared fundus photography
(Spectralis® HRA+OCT, Heidelberg Engineering, Heidel-berg, Germany), and venous blood analysis for HbA1c,
sodium, and potassium. Pupil dilation was made with
phenylephrine hydrochloride 10% and tropicamide 1%. *e
study eye of each patient was selected randomly except in
one patient where one eye was excluded because of diabetic
macular edema.
Study sessions followed a ﬁxed time schedule (Figure 1),
comprising two dark adaptation cycles beginning each with
infrared fundus photography in normal room light (ap-
proximately 200 lux) after 5 minutes of adaptation and
continuing with a second set of images after 20min of dark
adaptation and ﬁnally a third set of images after 40min of
dark adaptation. *e ﬁrst cycle was made with subjects
fasting, whereas the second cycle was started 65min after the
ingestion of the OGTT meal and thus made during post-
prandial hyperglycemia. Capillary blood glucose concen-
tration was measured (Precision Xceed reagent-strip and
reading device, Medisense Products, Abbott Laboratories,
Witney, Oxon, United Kingdom) immediately before and
after the two dark adaptation cycles. *e means of the two
pairs of glycemia values were used for data analysis.
Vessel diameters were assessed using a semiautomated
algorithm as previously described [23–25]. Central retinal
artery equivalent (CRAE) and central retinal vein equivalent
(CRVE) diameters were estimated from the individual
peripapillary vessel diameters according to the method of
Knudtson et al. [26], in this case measured on the infrared
fundus photographs.
*e same six arteriolar and six venular trunk vessel
segments were analyzed at a distance of one half to one disc
diameter from the optic disc. Vessel segments were mea-
sured along their entire length within this interval if no
crossing or branching was present. Trunk segments were
preferred to branches unless the trunk was shorter than
80 µm. *e diameters of the central vessel equivalents were
then calculated in the following manner:
arterioles: Ŵ � 0.88 × w21 + w
2
2( )
1/2
, (1)
venules: Ŵ � 0.95 × w21 + w
2
2( )
1/2
, (2)
where w1 is the width of the narrower branch, w2 is the
width of the wider branch, W is the estimate of the width of
the parent trunk arteriole or venule, and the constant is the
branching coeﬃcient. Vessel diameters, as measured or
derived from equations (1) or (2), were paired and used to
calculate trunk vessel width until only one number is left
representing the diameter of an idealized central retinal
artery or vein and named CRAE or CRVE [26].
Values for CRAE and CRVE were calculated from the
three best photographs from each time point and the mean
of the three values used for statistical analysis. *e photo-
graphs were ranked based on sharpness, disc centration, and
evenness of illumination.
*e statistical analysis included two-sample paired t-
tests of diﬀerences between fasting and hyperglycemic pa-
rameters and between light-adapted and dark-adapted pa-
rameters. Measurements are expressed as means± standard
deviations (mean± SD) and 95% conﬁdence intervals (CI95).
An operational level of statistical signiﬁcance of P≤ 0.05 is
used in the description of the results without correction for
multiple testing. Additionally, mixed model analysis for
repeated measurements with Tukey-adjusted comparisons
(SAS 9.4, SAS Institute, Carey, NC, USA) was used to model
the relative contributions of glycemia and dark adaptation to
the variations in CRAE and CRVE.
3. Results
Mean plasma glucose concentrations were 7.6± 1.7mM
during the fast and rose to 15.7± 4.2mM during
Table 1: Clinical characteristics of patients with type 2 diabetes.
Mean± SD
Age (years) 62.6± 7.5
Sex (male/female) 9/5
Duration of diabetes (years) 6.4± 5.0
Systolic blood pressure (mmHg) 131± 17
Diastolic blood pressure (mmHg) 76± 9
HbA1c (%) 7.3± 1.0
Visual acuity (Snellen) 1.0± 0.1
PG fasting (mM) 7.6± 1.7
PG 1.5-hour OGTT (mM) 15.7± 4.2
PG, plasma glucose; OGTT, oral glucose tolerance test.
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postprandial hyperglycemia (P< 0.01). From the fasting
baseline to hyperglycemia, in both cases before dark ad-
aptation was begun, retinal artery diameters decreased
signicantly from 170.7± 14.8 µm to 168.0± 13.8 µm
(P  0.025), whereas only a numerical reduction in vein
diameters was seen, from 227.0± 21.0 µm to 224.5± 20.8 µm
(P  0.127; Table 2; Figure 1).
While fasting, there was little change in retinal artery di-
ameters during dark adaptation, but from themore constricted
hyperglycemic baseline, dark adaptation was accompanied by
a 2.0% increase in retinal artery diameter, from 168.0± 13.8µm
to 171.4± 14.3µm at 20min (P  0.002) and 170.8± 15.0µm
or 1.7% more than that before dark adaptation at 40min
(P  0.022; Table 2).
While fasting, the retinal veins had dilated by 2.0% after 20
minutes, from 227.0± 21.0 µm to 231.5± 21.0 µm (P  0.018)
and by 2.9% after 40min, to 233.6± 23.1 µm (P  0.010;
Table 2; Figure 1). e retinal veins dilated, numerically,
during hyperglycemic dark adaptation, this time by 2.8%,
from a hyperglycemic daylight baseline of 224.5± 20.8 µm to
230.7± 25.4 µm after 20 minutes (P  0.026; Table 2) and
229.2 µm or 2.1% after 40 minutes (P  0.072).
In a mixed model analysis covering the entire data set in
a single model, we found nonsignicant interactions be-
tween glycemic state and dark adaptation, hence implying
independent eects. Dark adaptation had a highly signicant
eect on both CRAE and CRVE (P  0.001 and P< 0.0001,
respectively), leading to increases in vessel diameters in both
the fasting condition and during hyperglycemia (Figure 1).
Hyperglycemia was generally characterized by numerically
lower CRAE and CRVE, reected by statistical tendencies in
the mixed model analysis (P  0.10 and P  0.08).
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Figure 1: Retinal vessel diameter data indexed to baseline (triangles: arteries and squares: veins) in 14 patients with type 2 diabetes who were
fasting (glycemia 7.6± 1.7mM) and adapted to room light at baseline (0 minutes). is was followed by a cycle of dark adaptation and
fundus photography, during which infrared fundus photography, which had also been made at baseline, was repeated twice. Daylight was
reintroduced after 40 minutes and then, 5min later, participants ingested 75 g of glucose dissolved in water. After 70 more minutes when
glycemia had increased to 15.7± 4.2mM, infrared photographs were recorded in daylight, after which a second round of dark adaptation
and photography was reinitiated. PG, plasma glucose; OGTT, oral glucose tolerance test; IR, infrared. Values greater than 1 indicate vessel
dilation and values lower than 1 indicate vessel contraction. One-sided error bars indicate 1 standard deviation. Asterisk ∗1 indicates
P< 0.05 compared to the nearest predark adaptation baseline, fasting, or hyperglycemic. Asterisk ∗2 indicates P< 0.05 for a given time point
during the second (hyperglycemic) dark adaptation cycle compared to the rst (fasting) dark adaptation cycle.
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4. Discussion
*is experimental study of retinal vessel diameter variation
during acute hyperglycemia and dark adaptation in patients
with type 2 diabetes found that both dark adaptation and low
levels of glycemia were associated with wider retinal vessel
diameters. *e combined assessment of the two factors was
made possible by infrared digital fundus photography,
which does not disturb dark adaptation.
A tentative explanation is that dark adaptation leads to
vessel dilation because oxygen tension in the retina is lower in
the dark-adapted state than in daylight and that hypoglycemia
leads to vessel dilation because it reduces the energy substrate
supply to the retina. Presumably, but not actually documented
by our experiments, vasodilation compensates for energy
deﬁcits secondary to hypoxia and hypoglycemia by increasing
blood ﬂow and substrate supply to the retina. *e underlying
mechanisms may obviously be complicated, if extraocular
responses are elicited by changes in glycemia. *us, plasma
insulin, which should change during the glucose tolerance
test, was not measured in this study, but given that the pa-
tients had type 2 diabetes, they will have varying levels of
residual insulin production and insulin sensitivity. Insulin is
generally considered to have vasodilator eﬀects [27], so if
plasma insulin inﬂuenced the study, it likely acted to limit the
vasoconstrictive eﬀect of hyperglycemia by the endogenous
postprandial rise in insulin secretion [27, 28].
Our assumptions are supported by the demonstration by
Grunwald et al. that retinal vasodilation is associated with
increased retinal blood ﬂow [29] and that dark adaptation
increases retinal volumetric blood ﬂow in healthy subjects by
62–71% [8].
Retinal vasodilation during dark adaptation is consistent
with dark adaptation inducing an increase in metabolic
activity of the retina [7, 30]. Increased metabolism may
hypothetically promote the progression of diabetic reti-
nopathy [31, 32] because accompanying vasodilation and
hyperperfusion lead to increased shear stress on the vascular
endothelium. Relative hypoglycemia, by inducing vasodi-
lation, may have a comparable eﬀect. *is may help explain
why improved metabolic control in diabetes can lead to
short-term acceleration of retinopathy progression, despite
its long-term beneﬁts [33, 34]. Finally, our ﬁndings support
the suggestion that nocturnal vasodilation may explain why
diabetic macular edema tends to be more pronounced in the
morning than later in the day [35, 36].
*e vasoconstricting eﬀect of hyperglycemia may hy-
pothetically be driven by the ability of the retina to balance
its metabolic needs by increasing glycolysis and lactate
production, while decreasing oxidative phosphorylation and
CO2 production [12]. *e present study provides in-
formation only about the net result, however, and not about
its constituent components.
Limitations of this study include the lack of inclusion of
a group of healthy subjects. *is might determine whether
the characteristics in diabetes are an extension of normal
physiology induced by abnormally high postprandial rises in
blood glucose in diabetes or whether the physiological
characteristics or the retina has been adjusted, rearranged, or
disrupted by elevated and unstable glycemia or other aspects
of diabetes. Additionally, a larger study population might
have enabled analysis of the relation of vessel diameter
changes to age, blood pressure, HbA1c, and other variables of
interest. It should be noted that our results were obtained by
summarizing observations from a group of patients. We
have not shown that neither qualitative nor numerical re-
sponses can be used to deﬁne any clinically relevant char-
acteristics of patients with diabetes.
Table 2: Fasting and hyperglycemic retinal vessel diameters in patients with type 2 diabetes.
Patient
Fasting Hyperglycemia
Light Dark adaptation Light Dark adaptation
0min 20min 40min 0min 20min 40min
CRAE CRVE CRAE CRVE CRAE CRVE CRAE CRVE CRAE CRVE CRAE CRVE
1 191.0 257.0 189.4 265.7 189.7 271.3 181.2 249.8 189.8 274.6 194.2 269.2
2 175.0 222.2 176.8 231.4 170.9 225.7 169.5 219.6 171.6 227.2 168.8 225.0
3 181.7 234.3 182.5 239.7 191.7 253.6 186.8 239.0 190.3 256.4 189.2 255.7
4 160.3 220.8 166.2 232.2 162.4 235.8 154.7 222.1 163.1 230.4 162.7 227.6
5 176.5 245.6 176.6 245.7 177.4 252.2 176.7 248.0 176.6 247.3 180.6 246.0
6 169.7 246.0 173.2 248.3 174.9 264.1 169.2 248.4 173.3 264.5 173.5 263.7
7 150.7 189.7 153.1 203.4 153.7 199.0 147.5 184.4 154.2 196.8 151.5 195.4
8 178.5 225.5 178.6 225.9 173.5 226.3 174.9 220.7 180.6 221.2 178.3 220.8
9 142.8 206.7 145.0 206.4 144.3 205.8 141.0 199.1 140.7 194.5 139.7 196.3
10 190.2 250.0 187.8 248.6 184.2 243.3 184.1 244.4 182.7 238.5 181.1 234.7
11 153.7 214.1 155.1 217.6 154.3 217.4 155.8 216.7 154.9 215.5 157.2 217.6
12 185.8 245.6 181.7 239.4 180.6 240.2 177.4 230.5 182.5 237.0 181.7 235.5
13 167.9 192.6 171.0 194.3 170.0 197.3 165.3 195.1 168.6 192.2 164.0 192.3
14 166.6 227.2 172.7 242.8 168.6 238.8 167.3 225.8 170.0 234.0 168.9 228.7
MEAN 170.7 227.0 172.1 231.5 171.2 233.6 168.0 224.5 171.4 230.7 170.8 229.2
SD 14.8 21.0 13.2 21.0 13.8 23.1 13.8 20.8 14.3 25.4 15.0 24.3
AVR 0.75 0.74 0.73 0.75 0.74 0.75
All values are in µm. CRAE, central retinal artery equivalent; CRVE, central retinal vein equivalent.
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In summary, this study of patients with type 2 diabetes
found that dark adaptation was accompanied by retinal
vasodilation, both during normoglycemia and hyperglyce-
mia. Furthermore, the retinal vessels were dilated during
normoglycemia compared to postprandial hyperglycemia.
*e study supports that the occasional ﬂare-up of diabetic
retinopathy after rapidly introduced and strictly maintained
relative hypoglycemia [33, 34] may be precipitated by retinal
vasodilation and that rod photoreceptor activation may
promote worsening of diabetic retinopathy [32]. Our in-
terpretations can be tested in studies that include assessment
of perfusion rates and oxygenation, preferably with enough
participants and a long enough period of observation to
determine if individual vessel diameter responses can predict
retinopathy progression.
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